---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029671"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T22:59:22.843287+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics appoints breast cancer specialist Dr. Tessa Cigler to board

## Summary
- Dr. Cigler is a medical oncologist and clinical investigator at Weill Cornell Breast Center.
- She will serve as Class II director until 2026 annual meeting and on Nominating and Governance Committee.
- Appointment effective immediately; compensation follows standard non-employee director terms.
- Company's (Z)-endoxifen program has four Phase 2 trials; two expected to readout in H2 2024.
- Dr. Cigler holds M.D. from Duke, M.P.H. from Harvard, and extensive breast cancer clinical trial experience.

## SEC filing metadata
- accession: 0000950170-24-029671
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/0000950170-24-029671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/atos-20240309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029671
- JSON: https://secwatch.observer/filing/0000950170-24-029671.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029671.txt

## Key facts
- Executive change
  Tessa Cigler was appointed as Class II Director at ATOSSA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Class II Director
  source text: On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/0000950170-24-029671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.